A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

NCT02289950 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-Sensitive Ovarian Cancer in First Relapse

Interventions

DRUG: Farletuzumab
DRUG: Placebo

Sponsor

Eisai Inc.